W W Grainger Inc vs Immunovant Inc. Common Stock — how do they compare? W W Grainger Inc trades at $1,289.79 (market cap $59.76B), while Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B). The key difference: W W Grainger Inc is far larger — about 9.6× Immunovant Inc. Common Stock's market cap, and W W Grainger Inc pays a 0.79% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Immunovant Inc. Common Stock for 1 Days on average.
| GWW | IMVT | |
|---|---|---|
Market Cap | $59.76B | $6.25B |
Volume | 186,697 | 1,755,411 |
Sector | Industrials | Health |
52-Week High | $1.40K | $44.96 |
52-Week Low | $918.18 | $17.03 |
Typical Hold Time | 25 Days | 1 Days |
Enterprise Value | $61.96B | $5.35B |
Dividend Yield | 0.79% | — |
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,268.67, up 0.41% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong profitability with 47.92% ROE and 9.92% net margin, though valuation metrics appear elevated with a P/E of 32.34. Recent earnings show two consecutive beats, while analyst consensus leans heavily toward Hold (66.66%) with a $1,310 price target. The company continues strategic expansion with a new Oregon distribution center and technology acquisitions.
GWW presents a balanced outlook with solid fundamentals offset by premium valuation. The stock offers steady dividend growth as a Dividend King but faces headwinds from industrial sector challenges. Upside potential exists if earnings momentum continues, though current levels suggest limited near-term catalysts given the cautious analyst stance and technical resistance near $1,280-$1,303.
No Aura AI signal available yet.
Trailing returns across standard periods
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →